Humacyte Reaches Analyst Target Price
July 16, 2024 at 07:49 AM EDT
In recent trading, shares of Humacyte Inc (HUMA) have crossed above the average analyst 12-month target price of $8.25, changing hands for $8.40/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..